 |
ArchiveMorning Spy: Back To Reality (REE, HYGS, BYI, DFS, STEM, P, HLTOY, DTEGY)Posted by Eric Monte at 10:40AM on June 15th
The markets have reverted back to their old ways today as the S&P 500 is down almost 1%. The markets have struggled over the last month and are continuing that trend today. The move might be attributed to the CPI…  Select Stem Cell Stocks Surge After Favorable Court Ruling (PSTI, STEM, ATHX, ASTM, GERN, CUR, NBS, OSIR)Posted by Todd Shriber at 12:41PM on May 2nd
A ruling by federal appeals court last Friday allowing for continued government funding of human embryonic stem cell research is proving to be a major catalyst for select stem cells stocks, led by Pluristem Therapeutic (PSTI), which is surging 6%. Rival… Pluristem Shoots Higher On ‘Buy’ Rating (PSTI, ASTM, BTX, STEM, ATHX, CYTX, GERN)Posted by Todd Shriber at 12:01PM on January 10th
Pluristem Therapeutic (PSTI), the Israel-based bio-therapeutics firm, is up 13% today after National Securities initiated coverage of the maker of cell therapy products with a “buy” rating. National Securities is bullish on Pluristem’s cell delivery and homing capabilities and sees a… Stem Cell Stocks In Focus After Geron Publications (GERN, BTX, PSTI, ASTM, STEM, ISCO, KOOL, CUR)Posted by Jason Smith at 10:13AM on November 11th
Stem cell research firm Geron (GERN) spiked by 3% on Thursday after announcing two publications demonstrating that its clinical stage imetelstat drug targets cancer stem cells. Imetelstat, according to a company press release, is designed to inhibit telomerase, an enzyme that… Stem Cell Shares Rally On Court of Appeals Ruling (STEM, KOOL, CUR, ATHX, GERN)Posted by Jason Smith at 3:35PM on September 29th
The U.S. Court of Appeals lifted a ban on federally funded embryonic stem cell research on Tuesday, sending select components of the sector higher on domestic exchanges during Wednesday’s session. Back in August, District Judge Royce Lamberth hit the brakes… Stem Cell Shares Pop On Government Action (GERN, PSTI, STEM, CYTX, STEM, OPXA)Posted by Jason Smith at 12:34PM on September 9th
Recent legal disputes have put the stem cell sector in focus after District Judge Royce Lamberth hit the brakes on an executive order from the Obama administration, which had initially opened the door to federally funded research on human embryonic… StemCells Spikes On Study Results (STEM, CYTX, GERN, ASTM)Posted by Owen Vater at 10:37AM on August 19th
In a preclinical study, Palo Alto, California-based stem cell research firm StemCells (STEM) demonstrated that its proprietary human neural stem cells can restore motor function in the hind legs of paralyzed mice. According to the company announcement, it is the first… Two Healthcare Subsectors That Were Supposed To Rally (MDTH, THC, UHS, SEM, HMA, CUR, NBS, OPXA, STEM, GERN)Posted by Owen Vater at 3:45PM on July 8th
It’s been a strong month for various segments of the healthcare industry, but despite high hopes for hospitals and stem cell researchers, they have, for the most part, missed the boat on the latest equity rebound. Back in March, components of… Opexa Lifts Stem Cell Index (OPXA, NVS, NBS, KOOL, STEM, GERN, ASTM, CYTX, OSIR)Posted by Jason Smith at 11:40AM on March 30th
Stem cell stocks were mixed on Tuesday with Opexa Therapeutics (OPXA) exploding higher by 20%. The volatile stock saw its share of pops and drops in 2009 as a result of developments related to a deal with pharmaceutical giant Novartis (NVS), but… Opexa (OPXA) Spikes on Big Volume, No NewsPosted by Jason Smith at 2:25PM on March 3rd
Traders flocked to Opexa Therapeutics (OPXA) on Wednesday, sending shares higher by 9% on no news. Often-volatile Opexa shares have been stuck in a range of late, and traders decided to test short-term resistance near the $2.20 mark today. After soaring higher…  |
|
Follow us on
  |
| Home | Find | Research | Track | Register | My Account | Logout | Web site design by LightMix |
| © 2007-2013 Indie research Corp. All rights reserved. |